HE Meng-jiao, XIAO Yi-fang, KONG Xiang-an-ni, LIU Zhi-hao, WANG Xiao-guang, FENG Hao, TU Jia-sheng, CHEN Qian, SUN Chun-meng. Preparation modification strategies for clinical treatment drugs of Parkinson's diseaseJ. Acta Pharmaceutica Sinica, 2024, 59(3): 574-580. DOI: 10.16438/j.0513-4870.2023-0972
Citation: HE Meng-jiao, XIAO Yi-fang, KONG Xiang-an-ni, LIU Zhi-hao, WANG Xiao-guang, FENG Hao, TU Jia-sheng, CHEN Qian, SUN Chun-meng. Preparation modification strategies for clinical treatment drugs of Parkinson's diseaseJ. Acta Pharmaceutica Sinica, 2024, 59(3): 574-580. DOI: 10.16438/j.0513-4870.2023-0972

Preparation modification strategies for clinical treatment drugs of Parkinson's disease

  • Parkinson's disease (PD) is a chronic neurodegenerative disease. At present, levodopa and other drugs are mainly used for dopamine supplementation therapy. However, the absorption of levodopa in the gastrointestinal tract is unstable and its half-life is short, and long-term use of levodopa will lead to the end-of-dose deterioration, dyskinesia, the "ON-OFF" phenomenon and other symptoms. Therefore, new preparations need to be developed to improve drug efficacy, reduce side effects or improve compliance of patients. Based on the above clinical needs, this review briefly introduced the preparation modification strategies for the treatment of PD through case analysis, in order to provide references for the research and development of related preparations.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return